<DOC>
	<DOC>NCT01486940</DOC>
	<brief_summary>This trial is conducted in Europe and South America. The aim of this trial is to compare the glycaemic control of insulin detemir plus insulin aspart with that of insulin NPH plus human soluble insulin in subjects with type 1 diabetes on a basal/bolus regimen.</brief_summary>
	<brief_title>Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Isophane insulin, beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Isophane Insulin, Human</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 1 diabetes for at least 12 months Current treatment with any basal/bolus regimen or any biphasic insulin treatment for at least 6 months BMI below or equal to 35 kg/m^2 HbA1c below or equal to 12% Proliferative retinopathy or maculopathy requiring acute treatment Recurrent major hypoglycaemia that may interfere with trial participation (as judged by the Investigator) Subjects with known hypoglycaemic unawareness as judged by the Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>